New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 28, 2014
09:59 EDTMGLN, VRTS, DYAX, SBNY, BCRX, NCI, EPEOn The Fly: Analyst Initiation Summary
Magellan Health (MGLN) initiated with a Market Perform at Leerink... Virtus Investment Partners (VRTS) initiated with a Neutral at BofA/Merrill... Signature Bank (SBNY) coverage resumed with a Buy at Goldman... Dyax (DYAX) initiated with an Outperform at Oppenheimer... BioCryst (BCRX) initiated with a Perform at Oppenheimer... Navigant Consulting (NCI) initiated with a Buy at UBS... EP Energy (EPE) initiated with an Equal Weight at Morgan Stanley.
News For MGLN;VRTS;DYAX;SBNY;BCRX;NCI;EPE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 21, 2014
10:00 EDTSBNYOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:31 EDTSBNYSignature Bank upgraded to Outperform from Neutral at Boenning & Scattergood
Subscribe for More Information
09:03 EDTMGLNMagellan Health selects HMS unit for cost containment solutions
HMS, a wholly owned subsidiary of HMS Holdings (HMSY), announced that Magellan Health (MGLN) has selected HMS for cost containment solutions, including fraud, waste, and abuse detection and prevention across the company, as well as for insurance verification and subrogation services for Magellan Complete Care of Florida.
05:25 EDTSBNYSignature Bank reports Q3 EPS $1.52, consensus $1.46
Subscribe for More Information
October 20, 2014
15:36 EDTSBNYNotable companies reporting before tomorrow's open
Subscribe for More Information
09:09 EDTBCRXEMA encourages applications for orphan designation for Ebola treatments
The European Medicines Agency encourages developers of treatments or vaccines against Ebola to apply for orphan designation. Applications for orphan designation of Ebola medicines will be treated as a priority and EMA has committed to fast-tracking their evaluation, the regulator announced. Drug companies that are working on experimental Ebola vaccines and treatments include Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX), NewLink Genetics (NLNK) and GlaxoSmithKline (GSK).
October 19, 2014
16:44 EDTBCRXEbola drug discovery efforts intensify, WSJ says
Subscribe for More Information
13:39 EDTBCRXCarnival cruise passenger tests negative for Ebola, Reuters says
Subscribe for More Information
October 17, 2014
14:50 EDTBCRXBARDA asks labs to ramp up Zmapp production, Reuters says
Subscribe for More Information
09:46 EDTBCRXSarepta soars after publication of Ebola drug candidate data
Subscribe for More Information
October 15, 2014
10:49 EDTBCRXEbola linked names rise again amid broader market sell-off
Subscribe for More Information
October 14, 2014
11:19 EDTBCRXNIH says several potential Ebola treatments under development
Subscribe for More Information
10:12 EDTBCRXBioCryst, Chimerix move higher after mention in NIH director blog post
10:10 EDTBCRXNIH director says supporting BioCryst, Chimerix Ebola treatments
Subscribe for More Information
09:04 EDTBCRXChinese company says drug can cure Ebola, Reuters reports
Subscribe for More Information
October 12, 2014
19:26 EDTBCRXPatient being evaluated at Boston hospital for possible Ebola, Boston Globe says
Health officials say that a man that recently traveled to Liberia is being assessed at Beth Israel Deaconess hospital in Boston for the Ebola virus, the Boston Globe says. Drug companies that are working on experimental Ebola treatments include Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX) and NewLink Genetics (NLNK). Reference Link
19:12 EDTBCRXCDC confirms Texas healthcare worker positive for Ebola
Subscribe for More Information
14:18 EDTBCRXNY's JFK Airport begins Ebola screenings, WSJ says
Subscribe for More Information
12:48 EDTBCRXTexas health-care worker tests positive for Ebola, WSJ says
Subscribe for More Information
October 10, 2014
10:54 EDTBCRXMapp looking to up production of experimental Ebola treatment, WSJ says
Mapp Biopharmaceutical is aiming to broaden the manufacturing of its experimental Ebola treatment, ZMapp, according to The Wall Street Journal, citing comments from the company. Mapp said that the treatment was given to a few infected individuals prior to supplies running out two months ago. Drug companies that are working on experimental Ebola treatments include Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX) and NewLink Genetics (NLNK). Reference Link
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use